Adarigiline

Adarigiline

Clinical data
Drug class	Monoamine oxidase B (MAO-B) inhibitor
Identifiers
IUPAC name (4-hydroxypiperidin-1-yl)-[5-[4-methyl-5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophen-2-yl]methanone
CAS Number	1124197-79-0
PubChem CID	25211190
ChemSpider	64835238
UNII	YRT54V76ZY
Chemical and physical data
Formula	C15H15F3N2O3S
Molar mass	360.35 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(ON=C1C2=CC=C(S2)C(=O)N3CCC(CC3)O)C(F)(F)F
InChI InChI=1S/C15H15F3N2O3S/c1-8-12(19-23-13(8)15(16,17)18)10-2-3-11(24-10)14(22)20-6-4-9(21)5-7-20/h2-3,9,21H,4-7H2,1H3 Key:VXBWTNLAIBIATJ-UHFFFAOYSA-N

Adarigiline (INN Tooltip International Nonproprietary Name) is a monoamine oxidase inhibitor (MAOI) that was never marketed. ^{[1] [2] [3] [4]} It is specifically a monoamine oxidase B (MAO-B) inhibitor. ^{[1] [2] [3]} This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics. ^[5]

References

1. "-giline MAO-inhibitors type B C.3.1.0 (a) adarigiline (117),clorgiline (23), mofegiline (69), pargyline (13), rasagiline (70), selegiline (39), sembragiline (111)". Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (Stem book 2024) (PDF). World Health Organization. 2024. p. 112. ISBN   978-92-4-009938-8.
2. "Proposed INN: List 117 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 31 (2). 2017. tadarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone monoamine oxidase B inhibitor [...] C15H15F3N2O3S 1124197-79-0
3. "Recommended INN: List 79 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 32 (1). 2018. adarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone [...] C15H15F3N2O3S
4. "ADARIGILINE". Inxight Drugs. Retrieved 24 February 2025.
5. WO 2009/029632A1,Kaplan AP, Keenan TP, Mcriner AJ,"Therapeutic isoxazole compounds",published 5 March 2009, assigned to Helicon Therapeutics, Inc.